Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37

Futu NewsDec 16 20:31 · Ratings

Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target

BenzingaDec 16 19:58 · Ratings

Denali Therapeutics Analyst Ratings

BenzingaDec 16 19:57 · Ratings

Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.

BenzingaDec 7 02:03

Express News | Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease

BreakingsDec 5 21:00

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

GlobeNewswireDec 5 21:00